Source BioScience Completes Acquisition of Select Pharma Laboratories

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015
Volume 11
Issue 9

With this acquisition, Source BioScience is now able to offer integrated solutions to customers, with environmentally controlled storage in combination with the required up- or downstream analytical testing services.

Source BioScience announced that it has completed its acquisition of Select Pharma Laboratories, a provider of stability storage and testing services to the pharmaceutical, animal health, and medical devices sectors.

Based in Stirling, Scotland, Select’s portfolio of laboratory services includes chemistry, physical, and microbiological analyses for application in therapeutics batch release and product release to the EU market. Select operates from GMP-accredited facilities, and holds accreditations with the Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA).

With this acquisition, Source BioScience is now able to offer integrated solutions to customers, with environmentally controlled storage in combination with the required up- or downstream analytical testing services.

Nick Ash, CEO of Source BioScience said in a press statement, “The acquisition of Select will provide the company with the expertise and capability to provide stability testing services that are highly complementary to the group’s existing stability storage services. Significant cross-selling opportunities are apparent with our existing customer base, enabling them to reduce the number of service providers and de-risk the process by avoiding unnecessary sample transfers.”

Source: Source BioScience

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content